| 1 |
34904522 | Optimal pH 8.5 to 9 for the hydrolysis of vixotrigine and other basic substrates of carboxylesterase-1 in human liver microsomes. | 2022 Feb |
2 |
| 2 |
31871135 | Carboxylesterase 1 and Precision Pharmacotherapy: Pharmacogenetics and Nongenetic Regulators. | 2020 Mar |
1 |
| 3 |
32591414 | Natural Products as Modulators of CES1 Activity. | 2020 Oct |
2 |
| 4 |
31175950 | Discovery of natural pentacyclic triterpenoids as potent and selective inhibitors against human carboxylesterase 1. | 2019 Sep |
2 |
| 5 |
29464570 | Hepatic esterase activity is increased in hepatocyte-like cells derived from human embryonic stem cells using a 3D culture system. | 2018 May |
1 |
| 6 |
27895113 | Age-Dependent Absolute Abundance of Hepatic Carboxylesterases (CES1 and CES2) by LC-MS/MS Proteomics: Application to PBPK Modeling of Oseltamivir In Vivo Pharmacokinetics in Infants. | 2017 Feb |
3 |
| 7 |
28112927 | Selective Inhibitors of Human Liver Carboxylesterase Based on a β-Lapachone Scaffold: Novel Reagents for Reaction Profiling. | 2017 Feb 23 |
1 |
| 8 |
28437488 | The novel carboxylesterase 1 variant c.662A>G may decrease the bioactivation of oseltamivir in humans. | 2017 |
3 |
| 9 |
27228223 | Association of Oseltamivir Activation with Gender and Carboxylesterase 1 Genetic Polymorphisms. | 2016 Dec |
7 |
| 10 |
27638507 | Establishment and Characterization of a Novel Caco-2 Subclone with a Similar Low Expression Level of Human Carboxylesterase 1 to Human Small Intestine. | 2016 Dec |
1 |
| 11 |
25511794 | Effects of alcohol on human carboxylesterase drug metabolism. | 2015 Jun |
3 |
| 12 |
26262434 | Substrate-Competitive Activity-Based Profiling of Ester Prodrug Activating Enzymes. | 2015 Sep 8 |
4 |
| 13 |
24988246 | The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect. | 2014 |
1 |
| 14 |
25103325 | Physiologically based pharmacokinetic modeling of impaired carboxylesterase-1 activity: effects on oseltamivir disposition. | 2014 Sep |
5 |
| 15 |
22673926 | The effect of carboxylesterase 1 (CES1) polymorphisms on the pharmacokinetics of oseltamivir in humans. | 2013 Jan |
3 |
| 16 |
22588607 | Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans. | 2012 Jul |
4 |
| 17 |
21402544 | Surge in expression of carboxylesterase 1 during the post-neonatal stage enables a rapid gain of the capacity to activate the anti-influenza prodrug oseltamivir. | 2011 Apr 1 |
3 |
| 18 |
18983829 | Human carboxylesterases HCE1 and HCE2: ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin. | 2009 Jan 15 |
1 |
| 19 |
19022936 | Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants. | 2009 Feb |
6 |
| 20 |
18023188 | Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hydrolase (FAAH). | 2008 Feb 15 |
1 |
| 21 |
17578904 | Comments on "Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel". | 2007 Jul |
1 |
| 22 |
16966469 | Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. | 2006 Dec |
1 |